Skip to main content
main-content

29-09-2021 | ESMO 2021 | Conference coverage | Video

Dual EphrinB2 pathway, PD-1 inhibition shows promise in metastatic UC setting

Sarmad Sadeghi talks about their phase 2 trial pointing to the potential of combining the novel EphrinB2 pathway inhibitor sEphB4-HSA with pembrolizumab in previously treated patients with metastatic urothelial carcinoma (3:51).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Read transcript

Image Credits